Waddah B. Al-Refaie
Research Subjects
Research Interests
Waddah B. Al-Refaie has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Alexander Zeymo
MedStar-Georgetown Surgical Outcomes Research Center, Washington, DC; MedStar Health Research Institute, Washington, DC
3 shared publicationsLynt B. Johnson
Department of Surgery, MedStar-Georgetown University Hospital, 3800 Reservoir Road, Washington, DC, 20007, USA; MedStar-Georgetown Surgical Outcomes Research Center, 3800 Reservoir Road, Washington, DC, 20007, USA
3 shared publicationsNawar Shara
MedStar Health Research Institute, Washington, DC; Georgetown-Howard Universities Center for Clinical and Translational Science, Washington, DC
3 shared publications- James McDermott
The diaTribe Foundation, San Francisco, CA
2 shared publications Kitty S. Chan
MedStar-Georgetown Surgical Outcomes Research Center, Washington, DC; MedStar Health Research Institute, Washington, DC
2 shared publicationsNawar M. Shara
MedStar-Georgetown Surgical Outcomes Research Center, Georgetown University Hospital, Washington, DC; Department of Biostatistics and Bioinformatics, MedStar Health Research Institute, Hyattsville, MD; The Georgetown-Howard University Center for Clinical and Translational Science, Washington, DC
2 shared publications
Latest Publications
- 20 February 2019
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 23 (11) , 2119-2128
Evaluating Dissemination of Adequate Lymphadenectomy for Gastric Cancer in the USA
- 20 February 2019
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 23 (11) , 2119-2128
Evaluating Dissemination of Adequate Lymphadenectomy for Gastric Cancer in the USA
- 1 April 2016
- Published by Elsevier in The American Journal of Surgery
- Vol. 211 (4) , 750-754
Medicaid beneficiaries undergoing complex surgery at quality care centers: insights into the Affordable Care Act
- 1 April 2016
- Published by Elsevier in The American Journal of Surgery
- Vol. 211 (4) , 750-754
Medicaid beneficiaries undergoing complex surgery at quality care centers: insights into the Affordable Care Act
- 1 November 2015
- Published by Elsevier in Journal of Surgical Research
- Vol. 199 (1) , 97-105
Travel patterns of cancer surgery patients in a regionalized system
- 1 November 2015
- Published by Elsevier in Journal of Surgical Research
- Vol. 199 (1) , 97-105
Travel patterns of cancer surgery patients in a regionalized system
- 1 April 2013
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 216 (4) , 774-780
Does Enrollment in Cancer Trials Improve Survival?
Stakeholders derive many benefits from cancer clinical trials, including guidance for future oncologic treatment decisions. However, whether enrollment in cancer trials also improves patient survival independently of trial outcomes remains underinvestigated. We hypothesized that cancer trial enrollment is not associated with patient survival outcomes. Using the 2002 to 2008 California Cancer Registry, we identified 555,469 patients with stage I to IV solid organ tumors. Baseline characteristics were compared by trial participation status. Logistic regression determined predictors of trial enrollment. Multivariate Cox proportional hazards regression examined the impact of trial participation on overall and cancer-specific mortality with adjustment for covariates. Only 0.33% of our cohort was enrolled in clinical trials. Trial participants were likely to be younger than 65 (odds ratio [OR] 2.13; 95% CI 1.90 to 2.38), Hispanic rather than non-Hispanic white (OR 0.78; 95% CI 0.67 to 0.90), and have breast cancer (OR 3.14; 95% CI 2.62 to 3.77). Multivariate survival analyses demonstrated that enrollment in cancer trials predicted a lower hazard of death. However, when stratified by disease site, this survival benefit was observed only in lung, colon, and breast cancers. Sensitivity and interaction analyses confirmed these relationships. In this first population-based study examining trial effect in solid organ cancers, enrollment into cancer trials predicted lower overall and cancer-specific mortality among common cancer sites. Although these findings may demonstrate a survival benefit due to trial enrollment, they likely also reflect the favorable attributes of trial enrollees. Once corroborated, stakeholders must consider broader cancer trial designs representative of the cancer burden treated in the real world.
- 1 April 2013
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 216 (4) , 774-780
Does Enrollment in Cancer Trials Improve Survival?
Stakeholders derive many benefits from cancer clinical trials, including guidance for future oncologic treatment decisions. However, whether enrollment in cancer trials also improves patient survival independently of trial outcomes remains underinvestigated. We hypothesized that cancer trial enrollment is not associated with patient survival outcomes. Using the 2002 to 2008 California Cancer Registry, we identified 555,469 patients with stage I to IV solid organ tumors. Baseline characteristics were compared by trial participation status. Logistic regression determined predictors of trial enrollment. Multivariate Cox proportional hazards regression examined the impact of trial participation on overall and cancer-specific mortality with adjustment for covariates. Only 0.33% of our cohort was enrolled in clinical trials. Trial participants were likely to be younger than 65 (odds ratio [OR] 2.13; 95% CI 1.90 to 2.38), Hispanic rather than non-Hispanic white (OR 0.78; 95% CI 0.67 to 0.90), and have breast cancer (OR 3.14; 95% CI 2.62 to 3.77). Multivariate survival analyses demonstrated that enrollment in cancer trials predicted a lower hazard of death. However, when stratified by disease site, this survival benefit was observed only in lung, colon, and breast cancers. Sensitivity and interaction analyses confirmed these relationships. In this first population-based study examining trial effect in solid organ cancers, enrollment into cancer trials predicted lower overall and cancer-specific mortality among common cancer sites. Although these findings may demonstrate a survival benefit due to trial enrollment, they likely also reflect the favorable attributes of trial enrollees. Once corroborated, stakeholders must consider broader cancer trial designs representative of the cancer burden treated in the real world.